Related Experiment Video
Updated: May 17, 2026

Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery
Published on: February 20, 2017
Association between Androgenic Hormone Levels and Left Ventricular Ejection Fraction
Gholamreza Davoodi1, Alireza Amirzadegan, Mohammad Ali Boroumand
1Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Insights
Lower free testosterone (fT) levels are associated with reduced left ventricular ejection fraction (EF) in men. This finding suggests a link between androgen levels and heart failure severity, warranting further investigation.
Area of Science:
- Cardiology
- Endocrinology
- Heart Failure Research
Background:
- Androgens exert varied effects on the cardiovascular system.
- Previous research indicates a connection between androgens and cardiovascular health.
- This study investigates androgen levels in relation to left ventricular ejection fraction (EF).
Purpose of the Study:
- To compare androgenic hormone levels across different left ventricular ejection fraction (EF) groups.
- To identify potential associations between specific androgens and reduced EF.
- To explore the relationship between free testosterone (fT) and severe heart failure.
Main Methods:
- Analysis of 515 men undergoing echocardiography and coronary angiography.
- Classification of patients into four EF groups: <35%, 35-45%, 45-54%, and ≥55%.
- Measurement of serum androgens: free testosterone (fT), total testosterone (tT), and dehydroepiandrosterone sulfate (DHEAS).
- Comparative analysis between patients with EF <35% and EF ≥35%.
Main Results:
- Higher EF levels correlated with lower incidence of diabetes, coronary artery lesions, and C-reactive protein (CRP).
- A statistically significant trend was observed in baseline characteristics across EF groups.
- Patients with EF <35% exhibited significantly lower free testosterone (fT) levels compared to those with EF ≥35% (p < 0.05).
Conclusions:
- A significant association exists between reduced free testosterone (fT) levels and left ventricular ejection fraction (EF) <35%.
- The findings suggest a potential link between low fT and severe heart failure.
- Further prospective studies are needed to establish a causal relationship.
Background:
Androgens have been shown to have diverse effects on the cardiovascular system. The aim of this study was to compare androgenic hormone levels in patients with different left ventricular ejection fractions (EF).
Methods:
The study population consisted of 515 consecutive men who were referred for angiographic studies and whose results of echocardiography and coronary angiography were available. The patients were classified into four groups: EF < 35%, EF = 35-45%, EF = 45-54%, and EF ≥ 55% to evaluate the trends of baseline characteristics and serum androgens, including free testosterone (fT), total testosterone (tT), and dehydroepiandrosterone sulfate (DHEAS). To better elucidate the difference in the patients with severe heart failure, the patients were divided into two groups according to their EF level, and comparisons were repeated between those with EF < 35% and the ones with EF ≥ 35%.
Results:
There were statistically significant trends in some characteristics in the patients with different levels of EF. The subjects with higher EF levels were less likely to have diabetes (p value < 0.001), coronary artery lesion (p value < 0.001), or high levels of C-reactive protein (CRP) (p value < 0.001). As regards the patients with severe heart failure, our regression analysis revealed that the fT level was significantly lower in those with EF < 35% than in the ones with EF ≥ 35% (5.82 ± 2.73 pg/mL vs. 6.88 ± 3.34 pg/mL, p value < 0.05).
Conclusion:
A significant association was found between the level of fT and EF < 35%. There is a need for further controlled prospective studies to delineate any possible causal relationship accurately.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Mitral Regurgitation I: Introduction